Filtered By:
Condition: Ischemic Stroke
Cancer: Prostate Cancer
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 56 results found since Jan 2013.
Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
Androgen deprivation therapy (ADT) in the treatment of prostate cancer may be associated with an increased risk of thromboembolic disease. The aim of our study was to investigate the association of ADT in the ...
Source: BMC Cancer - December 30, 2019 Category: Cancer & Oncology Authors: Kuang-Ming Liao, Yaw-Bin Huang, Chung-Yu Chen and Chen-Chun Kuo Tags: Research article Source Type: research
Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naïve prostate cancer.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Jong-Mi Seong, Dongho Shin, Jae Woo Sung, Shinjay Cho, Jonghyup Yang, Sungmin Kang, Hyong Woo Moon, Kyu Won Lee, U-Syn Ha Tags: Research Paper Source Type: research
Perlecan, a Modular Instructive Proteoglycan with Diverse Functional Properties.
This study reviewed some new aspects of the modular proteoglycan perlecan, a colossal proteoglycan with a 467 kDa core protein and five distinct functional domains. Perlecan is a heparan sulphate proteoglycan that transiently displays native CS sulphation motifs 4-C-3 and 7-D-4 during tissue morphogenesis these are expressed by progenitor cell populations during tissue development. Perlecan is susceptible to fragmentation by proteases during tissue development and in pathological tissues particularly in domains IV and V. The fragmentation pattern of domain IV has been suggested as a means of grading prostate cancer. Doma...
Source: The International Journal of Biochemistry and Cell Biology - September 14, 2020 Category: Biochemistry Authors: Melrose J Tags: Int J Biochem Cell Biol Source Type: research
Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Diffusion-Weighted MRI in the Genitourinary System
In conclusion, DWI constitutes a major advancement in genitourinary imaging with a central role in decision algorithms in the female pelvis and prostate cancer, now allowing promising applications in renal imaging or in the bladder and testicular mpMRI.PMID:35407528 | DOI:10.3390/jcm11071921
Source: Clinical Prostate Cancer - April 12, 2022 Category: Cancer & Oncology Authors: Thomas De Perrot Christine Sadjo Zoua Carl G Glessgen Diomidis Botsikas Lena Berchtold Rares Salomir Sophie De Seigneux Harriet C Thoeny Jean-Paul Vall ée Source Type: research
ADT Use for Prostate Cancer Linked to Increased Risk for CVD Death
Risk increased for CVD death and for death from ischemic heart disease and stroke, especially among those aged 70 to 79 years
Source: The Doctors Lounge - Oncology - July 29, 2022 Category: Cancer & Oncology Tags: Cardiology, Internal Medicine, Oncology, Pharmacy, Urology, Geriatrics, Journal, Source Type: news
Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 to 2017
CONCLUSIONS: In contrast to declining trends in patients without cancer, primary cardiovascular admissions in patients with cancer is increasing. The highest admission rates are in patients with hematological cancer and the most common cause of admission is heart failure.PMID:35913736 | DOI:10.1093/ehjqcco/qcac045
Source: Clinical Prostate Cancer - August 1, 2022 Category: Cancer & Oncology Authors: Ofer Kobo Zahra Raisi-Estabragh Sofie Gevaert Jamal S Rana Harriette G C Van Spall Ariel Roguin Steffen E Petersen Bonnie Ky Mamas A Mamas Source Type: research
